TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00894998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heparin sodium - Cristália
Description: Heparin sodium 5000UI - Cristália

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sodium APP
Description: Heparin Sodium 5.000 USP - APP
Study: NCT00501956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradialytic Parenteral Nutrition (IDPN)
Description: compounded IDPN, 3 x/week, 16 weeks intervention
Study: NCT05612451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative Endodontic Procedures
Description: Regenerative Endodontic procedures were performed by one operator following similar protocols according to the clinical considerations for a regenerative procedure advised by the American Association of Endodontists and European Society of Endodontology

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative Endodontic Procedures
Description: Regenerative Endodontic procedures were performed by one operator following similar protocols according to the clinical considerations for a regenerative procedure advised by the American Association of Endodontists and European Society of Endodontology

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-setting calcium hydroxide
Description: non-setting calcium hydroxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified triple antibiotic paste
Description: modified triple antibiotic paste
Study: NCT01494545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lens
Description: Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
Study: NCT01316965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted prevention program HELP(Hospital Elder Life Program)
Description: * A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~* B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~* C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium.
Study: NCT02038998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exer-Rest® TL
Description: Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
Study: NCT04634032

Intervention type: GENETIC
Intervention: mRNA expression and SNP analysis
Description: mRNA expression and SNP analysis from samples

Intervention type: GENETIC
Intervention: mRNA expression and SNP analysis
Description: mRNA expression and SNP analysis from samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Peripheral blood sampling for SNP analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Peripheral blood sampling for SNP analysis
Study: NCT01857102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Soft contact lens to be worn in a daily wear, daily disposable modality for one week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Soft contact lens to be worn in a daily wear, daily disposable modality for one week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A for Astigmatism
Description: Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A for Astigmatism
Description: Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
Study: NCT03654391

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: InnoSlim
Description: Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure \[SBP\] and diastolic blood pressure \[DBP\]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
Study: NCT04026334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline
Description: -125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
Study: NCT00422422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~* \~0.4 mg/kg bid for Week 1~* \~0.8 mg/kg bid for Week 2~* \~1.6 mg/kg bid for Week 3~For subjects \<8 years:~* \~0.5 mg/kg bid for Week 1~* \~1.0 mg/kg bid for Week 2~* \~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~* \~0.8 mg/kg bid for Week 4~* \~0.4 mg/kg bid for Week 5~For subjects \<8 years:~* \~1.0 mg/kg bid for Week 4~* \~0.5 mg/kg bid for Week 5
Study: NCT02346994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melt Test Blend 3.2
Description: Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn Oil
Description: Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
Study: NCT01701505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400uL of Kovacaine Mist
Description: 2 unilateral intranasal sprays of 200uL each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200uL of Kovacaine Mist
Description: 2 unilateral intranasal sprays of 100uL each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120uL of Kovacaine Mist
Description: 2 unilateral intranasal sprays of 60uL each.
Study: NCT03469999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dysport Injectable Product
Description: Selected dose of medication will be determined by affected muscle(s), severity of spasticity, and the patient's body weight. We will follow the recommended total Dysport dose of 10-15 units/kg per limb, not to exceed 15 units/kg for unilateral lower limb, 30 units/kg for bilateral lower limb, or a total of 1000 units, whichever is lower in a given session.
Study: NCT00568568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
Study: NCT01900899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: At 2, 3, 4, 5, 6 years after booster vaccination.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sampling
Description: At 2, 3, 4, 5, 6 years after booster vaccination.
Study: NCT03947502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention in neurobiology of pain
Description: The educational intervention will intend to make the individual aware that in the processes of learning, sensitization, habituation and acquisition of beliefs about pain there are automatic unconscious mechanisms, which can be modulated through conscious behaviors. Based on this the investigators propose the active participation of patients in the process of desensitization of their central nervous system. The investigators will try to encourage attention and weaken the neuronal connections that make up the pain neuromatrix to establish new connections thanks to neuroplasticity.
Study: NCT02020512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.03% Bimatoprost
Description: 0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
Study: NCT00586898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: leuprolide and goserelin are gonadotropin-releasing hormone analogues

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: An imidazole antifungal agent. reduces adrenal and testicular androgen production in men

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: A pure nonsteroidal antiandrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone transdermal gel
Description: an androgenic anabolic steroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen transdermal patch
Description: Estradiol is the primary and most potent estrogen
Study: NCT01356329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin, Heparin
Description: Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin, Heparin
Description: Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician.
Study: NCT03439462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: nab-sirolimus combined with mFOLFOX6 + bevacizumab
Study: NCT01481272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamid
Description: 1500mg/m2 or 1000mg/m2 (patients \>/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 300mg/m2 or 200mg/m2 (patients \>/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients \>/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2 or 0,5-1g/m2 (patients \>/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukovorin
Description: 15mg, po 24 hours after methotrexate it

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-Colony Stimulating Factor
Description: 5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC\>1.0x109/l
Study: NCT03567161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cavitron ultrasonic surgical aspirator
Description: Cavitron Ultrasonic Surgical Aspirator (CUSA) has proven to be effective in biofilm disruption and cell stimulation . The hypothesis is that the employment of CUSA for non-surgical treatment of infrabony defects thanks to its abilities to disrupt, fragment and aspirate granulation tissue, will allow the formation of larger and more stable blood clot.~According to the anatomy of the osseous sites, the sonotrode (Sonocare 300 by Söring GmbH, Justus-von-Liebig-Ring 2 -25451 Quickborn Germany) will be inserted both intrasulcularly and trans gingivally (smallest tip is 0,8 mm); intrasulcularly in the cases of three wall defects, and trans gingivally in cases of one to two wall defects .
Study: NCT01832909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut Diet
Description: Controlled diet with 1.5 oz/d of walnuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut Diet
Description: Controlled diet with 1.5 oz/d of walnuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: Controlled diet without walnuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: Controlled diet without walnuts.
Study: NCT01084213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment of malaria in pregnancy (IST)
Description: Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP-IPTp
Description: Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
Study: NCT00878605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z
Description: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z
Description: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclo-Z
Description: Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT01443325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch
Description: 1 patch for 12 hours within each 24 hours period
Study: NCT00194194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: moderate
Description: moderate behavioral management with RD

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting Metablic Rate measurements
Description: intensive behavior management
Study: NCT03467334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. breve
Description: Bifidobacterium probiotic strain at 1E+08 cfu/day
Study: NCT02038998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exer-Rest® TL
Description: Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exer-Rest® TL
Description: Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
Study: NCT00344032

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study: NCT03467334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. breve plus L. fermentum
Description: Probiotic combination at 2E+08 cfu/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone 20 MG
Description: Standard treatment for infant colic
Study: NCT01978678

Intervention type: DRUG
Intervention: Pulmicort
Description: ACQ and FeNO
Study: NCT01918878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (EYLEA)
Description: INTARAVITREAL INJECTION OF AFLIBERCEPT
Study: NCT03517137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.
Study: NCT02546908

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
Study: NCT00656500

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard brief advice
Description: Brief general assistance with smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline intervention
Description: Brief intervention designed specifically to encourage quitline utilization
Study: NCT00996190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
Study: NCT01236833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's Solution
Description: 2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
Study: NCT02625831

Intervention type: OTHER
Intervention: Biological analysis
Description: Biological analysis :~* ficolin-3~* anti-ficolin 3 antibodies~* anti-C1q antibodies

Intervention type: OTHER
Intervention: Biological analysis
Description: Biological analysis :~* ficolin-3~* anti-ficolin 3 antibodies~* anti-C1q antibodies
Study: NCT02739542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tecfidera
Description: Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
Study: NCT00344032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study: NCT02994056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.